Synthesis and antirheumatic activity of novel tetrahydro-6-quinolineacetic acid derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 12, 1997, Pages 1519-1524

  Kohno, Yasushi ^a   Awano, Katsuya ^a   Miyashita, Mitsutomo ^a   Ishizaki, Takayoshi ^a   Kuriyama, Kazuhiko ^a   Sakoe, Yasuhiko ^a   Kudoh, Shinji ^a   Saito, Koji ^a   Kojima, Eisuke ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; DICLOFENAC; IRA 378; NITRIC OXIDE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE DESTRUCTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; IMMUNE RESPONSE; IN VITRO STUDY; INFLAMMATION; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

EID: 0031011821     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00262-X     Document Type: Article

References (16)

1. American College of Rheumatology Ad Hoc Committee on Clinical Guidlines, Arthritis & Rheumatism, 39, 713 (1996).
2. Kohno Y.; Awano K.; Miyashita M.; Fujimori S.; Sakoe Y.; Kudoh S.; Saito K.; Kojima E., Bioorg. Med. Chem. Lett. submitted (the preceding paper).
3. We carried out the acetic acid-induced vascular permeability experiment according to the method of Whittle A., Br. J. Pharmacol., 22, 246 (1964).
4. -8 M.
5. Adjuvant arthritis was induced in SD rats according to the method of Kameyama et al.: Kameyama T.; Nabeshima T.; Yamada S.; Sato M., Arzneim-Forsch/Drug Res., 37, 19 (1987). After the adjuvant injection, drug treatment (p.o.) was started on Day 14 and continued until Day 20 (once daily, 7 treatments). Suppressive rate on edema was calculated on Day 21.
6. 2, the number of IgM antibody-producing cells was counted by Jerne method: Jerne N. K.; Nordin A. A., Science, 140, 405 (1963).
7. 8 cells/0.1 ml PBS) were intraperitoneally injected to a BALB/c mice. The test compounds were administered orally once daily for 4 consecutive days after the erythrocyte injection. On the next day of final administration, the spleen cells were isolated by finely mincing the spleen, then centrifuging and suspending in medium (RPMI-1640 + 10% FCS). The number of IgM antibody-producing cells was counted by Jerne method. 8k showed inhibition of 35% (p<0.05) at a dose of 12.5 mg/kg.
8. 2: C, 49.08; H, 3.78; N, 4.77. Found: C, 49.15; H. 3.61; N, 4.76.
9. 50 value of IRA-378 was about 25 mg/kg. In comparing suppressive patterns of them, the above doses (diclofenac-Na 0.5 mg/kg, IRA-378 25 mg/kg) which both of compounds would display same effect were adopted.
10. (a) Pozo E. D.; Graeber M.; Elford P.; Payne T., Arth. Rheum., 33, 247 (1990).
11. (b) Binderup L., Acta Pharmacol. Toxicol., 59, 228 (1986).
12. On day 27, radiographic assessment of non-injected paws was done by a modification of the method of Tanaka et al.: Tanaka A.; Kakushi H.; Shike T.; Yoshida T.; Kojima Y.; Nishiyama S.; Yahara I., Oyo Yakuri-Pharmacometrics, 24, 571 (1982). Bone damage was assessed blindly on a scale of 0-4+ (with 0 equaling normal and 4+ equaling severe changes) for metatarsus, tarsus, calcaneum and the end of the distal tibia of the non-injected paw. The maximum total severity score by this method was 16+.
13. Bone resorption was measured according to a modification of the method in Tsuda et al.: Tsuda M.; Kitazaki T.; Ito T.; Fujita T., J. Bone Miner. Res., 1, 207 (1986).
14. (a) Stefanovic-Racic M.; Meyers K.; Meschter C.; Coffey J. W.; Hoffman R. A.; Evans C. H., Arthritis & Rheumatism, 37, 1062 (1994).
15. (b) Connor J. R.; Manning P. T.; Settle S. L.; Moore W. M.; Jerome G. M.; Webber R. K.; Tjoeng F. S.; Currie M. G., Eur. J. Pharmacl., 273, 15 (1995).
16. Salvemini D.; Manning P. T.; Zweifel B. S.; Seibert K.; Connor J.; Currie M. G.; Needleman P.; Masferrer J. L., J. Clin. Invest., 96, 301 (1995).